K-Farma SRL
K-Farma reported total assets of €1.94m at the end of the 2025 financial year (annual accounts filed with the NBB on 03 Jun 2026).
By total assets for 2025, K-Farma ranks among the 500 largest of the 3,805 companies in its sector (NACE 4773) in Belgium that filed accounts for that financial year. Largest companies in the sector →
The score of K-Farma shows with a free account.
See the score- Summary? / 5
- Balance sheet strength
- Liquidity
- Repayment capacity
- Profitability
- Trajectory
- Compliance and register
- Position in its sectorvs peers
- Supplier creditat 30 d
- Borrowing capacityborrowable
- Valuationcentral
Visible once signed in: create your account, the 14-day Pro trial is free.
Key figures 2025
Accounts of the company itself (not consolidated).
The full file covers 2 financial years; a free account shows 2. →Deterministic calculation on the filed accounts, no AI. Dispute the score or report an error
K-Farma's annual accounts
Filed annual accounts
- Year ended 31 Dec 2025filed on 03 Jun 2026
- Year ended 31 Dec 2024filed on 02 Jun 2025
K-Farma's financial analysis
- Solvency8.7%sector median: 44.0%
- Current ratio
- Net margin
- ROE
- Financial debt / EBITDA
- Interest coverage
- Days sales outstanding (DSO)
Management and control of K-Farma
K-Farma's publications in the Belgian Gazette
Company number, VAT number and registered office
- Company number (CBE)
- 1001.785.712
- VAT number
- BE1001785712
- Peppol
- Registered · 0208:1001785712 · as of 10 Nov 2026
- Legal form
- SRL
- Incorporated
- 30 Oct 2023
- Registered office
- 2242 Zandhoven
- Latest accounts
- 2025 · filed on 03 Jun 2026
- Activity
- Retail sale of pharmaceutical products (NACE 47730)
K-Farma (SRL) has been based in Zandhoven since 2023, active in: retail sale of pharmaceutical products. For 2025, it reports a net profit of 122,831 € and equity of 168,173 €; its revenue is not published. Its solvency stands at 8.7%, below the median of its sector (44.0%).
Guide: Reading Belgian SME accounts: the five figures that count →
Companies similar to K-Farma
Companies in the same business, of comparable size and area, outside its group.
- Groupe Tete Pharmaceutical Manufacture of basic pharmaceutical products Nivelles · balance sheet €1.15m
- ANAP Retail sale of pharmaceutical products Aalst · balance sheet €1.37m
- Varmaca Retail sale of pharmaceutical products Peer · balance sheet €2.03m
- Apotheek Schellekens - Lauwers Retail sale of pharmaceutical products Schelle · balance sheet €1.84m
- APR.P.D. Retail sale of pharmaceutical products Hasselt · balance sheet €2.05m
- Markri-Farma Retail sale of pharmaceutical products Herent · balance sheet €2.60m
- Pharmacie d'Helecine Retail sale of pharmaceutical products Hélécine · balance sheet €1.22m
- Thomas Broos Retail sale of pharmaceutical products Herent · balance sheet €1.19m
Frequently asked questions about K-Farma
What is the revenue of K-Farma?
K-Farma files its accounts in a format where revenue is optional: it is not published for 2025.
What is the VAT number of K-Farma?
In Belgium, the VAT number is the company number prefixed with BE: BE1001785712 for K-Farma, if the company is VAT-registered. Its company number (CBE) is 1001.785.712.
Where is the registered office of K-Farma?
According to the CBE register, the registered office of K-Farma is in 2242 Zandhoven.
What is the equity of K-Farma?
At the close of the 2025 financial year, the equity of K-Farma amounts to 168,173 €, a solvency of 8.7% of total assets.
Who manages K-Farma?
The register lists 1 active mandates at K-Farma. Names and roles are in the full file, with the deeds published in the Belgian Gazette.
How large is K-Farma within its sector?
By total assets for 2025, K-Farma ranks among the 500 largest of the 3,805 companies in its sector (NACE 4773) in Belgium that filed accounts for that financial year.
The full file of K-Farma
Directors and mandates, ownership network, Gazette deeds, ten years of accounts and ratios, Excel export, and Idonis's analysis in one question.
Open the full file →